Current Report Filing (8-k)
November 10 2022 - 04:05PM
Edgar (US Regulatory)
false 0001435049 0001435049 2022-11-10
2022-11-10
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 10,
2022
Chinook Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
Delaware
(State or other jurisdiction of incorporation)
|
001-37345
|
|
|
94-3348934
|
|
(Commission
File No.)
|
|
|
(IRS Employer
Identification No.)
|
400 Fairview Avenue North, Suite 900
Seattle, WA
(Address of principal executive offices)
98109
(Zip Code)
Registrant’s telephone number, including area code: (206)
485-7241
Not applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2.
below):
|
☐
|
Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)
|
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12)
|
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
|
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
|
Common Stock, par value $0.0001 per share
|
KDNY
|
The Nasdaq Stock Market LLC
(The Nasdaq Global Select Market)
|
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933
(§ 230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
☐
|
Item 2.02.
|
Results of Operations and Financial Condition.
|
On November 10, 2022, Chinook Therapeutics, Inc. (“Chinook”)
announced certain financial results for the third quarter ended
September 30, 2022. A copy of Chinook’s press release, titled
“Chinook Therapeutics Provides Business Update and Reports Third
Quarter 2022 Financial Results” is furnished pursuant to Item 2.02
as Exhibit 99.1 hereto.
|
Item 9.01.
|
Financial Statements and Exhibits.
|
The information in this report, including the exhibit hereto, shall
not be deemed to be “filed” for purposes of Section 18 of the
Securities Exchange Act of 1934, as amended, or otherwise subject
to the liabilities of that Section 11 and 12(a)(2) of the
Securities Act of 1933, as amended. The information contained
herein and in the accompanying exhibit shall not be incorporated by
reference into any filing with the U.S. Securities and Exchange
Commission made by Chinook Therapeutics, Inc., whether made before
or after the date hereof, regardless of any general incorporation
language in such filing.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the Registrant has duly caused this report to be signed on
its behalf by the undersigned hereunto duly authorized.
|
Dated: November 10, 2022
|
|
|
|
Chinook Therapeutics, Inc.
|
|
|
|
|
|
|
|
|
|
By:
|
|
/s/ Eric L. Dobmeier
|
|
|
|
|
|
Eric L. Dobmeier
|
|
|
|
|
|
President and Chief Executive Officer
|
Aduro Biotech (NASDAQ:ADRO)
Historical Stock Chart
From Dec 2022 to Jan 2023
Aduro Biotech (NASDAQ:ADRO)
Historical Stock Chart
From Jan 2022 to Jan 2023
